Literature DB >> 24052573

Hypomorphic mutation in the RAG2 gene affects dendritic cell distribution and migration.

Virginia Maina1, Veronica Marrella, Stefano Mantero, Barbara Cassani, Elena Fontana, Achille Anselmo, Annalisa Del Prete, Silvano Sozzani, Paolo Vezzoni, Pietro Luigi Poliani, Anna Villa.   

Abstract

OS is a severe combined immunodeficiency characterized by erythrodermia and protracted diarrhea as a result of infiltration of oligoclonal-activated T cells, caused by hypomorphic mutations in RAGs. The RAG2(R229Q) mouse model fully recapitulates the clinical OS phenotype. We evaluated whether T and B cell defects, together with the abnormal lymphoid structure, could affect DC homeostasis and function. High density of LCs was observed in skin biopsies of Omenn patients and in the derma of RAG2(R229Q) mice, correlating with the presence of erythrodermia. In vivo models of cutaneous skin painting and CHS demonstrated a decreased migration of RAG2(R229Q) DCs-in particular, LCs-into draining LNs. Interestingly, at steady state, RAG2(R229Q) mice showed a reduction in DC number in all hematopoietic organs except LNs. Analysis of the MHCII marker revealed a diminished expression also upon the LPS-driven inflammatory condition. Despite the decreased number of peripheral DCs, BM pre-cDCs were present in normal number compared with RAG2(+/+) controls, whereas pDCs and monocytes were reduced significantly. Overall, these results point to a secondary defect in the DC compartment, which contributes to clinical manifestations and autoimmunity in OS.

Entities:  

Keywords:  Omenn syndrome; immune dysregulation; primary immunodeficiency

Mesh:

Substances:

Year:  2013        PMID: 24052573     DOI: 10.1189/jlb.0713365

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  5 in total

Review 1.  RAG gene defects at the verge of immunodeficiency and immune dysregulation.

Authors:  Anna Villa; Luigi D Notarangelo
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

2.  Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation.

Authors:  Valentina Capo; Maria Carmina Castiello; Elena Fontana; Sara Penna; Marita Bosticardo; Elena Draghici; Luigi P Poliani; Lucia Sergi Sergi; Rosita Rigoni; Barbara Cassani; Monica Zanussi; Paola Carrera; Paolo Uva; Kerry Dobbs; Nicolò Sacchetti; Luigi D Notarangelo; Niek P van Til; Gerard Wagemaker; Anna Villa
Journal:  J Allergy Clin Immunol       Date:  2017-12-11       Impact factor: 10.793

3.  Intestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects.

Authors:  Rosita Rigoni; Elena Fontana; Simone Guglielmetti; Bruno Fosso; Anna Maria D'Erchia; Virginia Maina; Valentina Taverniti; Maria Carmina Castiello; Stefano Mantero; Giovanni Pacchiana; Silvia Musio; Rosetta Pedotti; Carlo Selmi; J Rodrigo Mora; Graziano Pesole; Paolo Vezzoni; Pietro Luigi Poliani; Fabio Grassi; Anna Villa; Barbara Cassani
Journal:  J Exp Med       Date:  2016-02-29       Impact factor: 14.307

4.  Cutaneous barrier leakage and gut inflammation drive skin disease in Omenn syndrome.

Authors:  Rosita Rigoni; Elena Fontana; Kerry Dobbs; Veronica Marrella; Valentina Taverniti; Virginia Maina; Amanda Facoetti; Giovanna D'Amico; Waleed Al-Herz; Mario Ernesto Cruz-Munoz; Catharina Schuetz; Andrew R Gennery; Elizabeth K Garabedian; Silvia Giliani; Deborah Draper; Ghassan Dbaibo; Raif S Geha; Isabelle Meyts; Thomas Tousseyn; Benedicte Neven; Despina Moshous; Alain Fischer; Ansgar Schulz; Andrea Finocchi; Douglas B Kuhns; Danielle L Fink; Michail S Lionakis; Muthulekha Swamydas; Simone Guglielmetti; Julie Alejo; Ian A Myles; Stefania Pittaluga; Luigi D Notarangelo; Anna Villa; Barbara Cassani
Journal:  J Allergy Clin Immunol       Date:  2020-04-18       Impact factor: 10.793

Review 5.  Rag defects and thymic stroma: lessons from animal models.

Authors:  Veronica Marrella; Pietro Luigi Poliani; Luigi Daniele Notarangelo; Fabio Grassi; Anna Villa
Journal:  Front Immunol       Date:  2014-06-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.